uniQure (NASDAQ:QURE) Short Interest Update

uniQure (NASDAQ:QURE - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 4,390,000 shares, an increase of 43.9% from the March 15th total of 3,050,000 shares. Currently, 9.5% of the company's stock are short sold. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is presently 3.8 days.uniQure Stock PerformanceShares of NASDAQ:QURE traded up $3.61 during midday trading on Friday, hitting $13.00. The stock had a trading volume of 14,440,345 shares, compared to its average volume of 1,738,888. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a 50 day moving average price of $11.89 and a two-hundred day moving average price of $11.18. The company has a market capitalization of $703.00 million, a PE ratio of -2.62 and a beta of 0.42. Analyst Upgrades and DowngradesA number of equities research analysts recently weighed in on the stock. Wells Fargo & Company reduced their price target on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research report on Friday, February 28th. Royal Bank of Canada reissued an "outperform" rating and issued a $24.00 target price on shares of uniQure in a report on Tuesday, January 21st. Mizuho raised their price target on uniQure from $7.00 to $20.00 and gave the stock a "neutral" rating in a research note on Thursday, December 19th. Chardan Capital started coverage on uniQure in a research note on Tuesday, April 1st. They issued a "buy" rating and a $38.00 price objective for the company. Finally, StockNews.com raised shares of uniQure to a "sell" rating in a report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, uniQure has an average rating of "Moderate Buy" and an average target price of $38.80.Read Our Latest Research Report on QUREInsider Buying and Selling at uniQureIn other news, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $291,628.89. Following the transaction, the chief executive officer now owns 651,454 shares in the company, valued at approximately $6,703,461.66. This represents a 4.17 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Christian Klemt sold 2,916 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $33,009.12. Following the sale, the chief financial officer now owns 155,168 shares of the company's stock, valued at approximately $1,756,501.76. The trade was a 1.84 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 90,830 shares of company stock valued at $961,401. Insiders own 4.74% of the company's stock. Institutional Investors Weigh In On uniQureInstitutional investors have recently added to or reduced their stakes in the business. Twin Tree Management LP purchased a new position in shares of uniQure during the 4th quarter worth approximately $77,000. FNY Investment Advisers LLC purchased a new position in uniQure in the fourth quarter worth $88,000. ADAR1 Capital Management LLC acquired a new stake in uniQure in the fourth quarter valued at $177,000. China Universal Asset Management Co. Ltd. boosted its position in shares of uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock worth $195,000 after purchasing an additional 969 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock worth $217,000 after purchasing an additional 1,503 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock. About uniQure (Get Free Report)uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.Recommended StoriesFive stocks we like better than uniQureOverbought Stocks Explained: Should You Trade Them?3 Mid-Cap to Mega-Cap Stocks Have Announced Significant BuybacksHow to Invest in Tech Stocks and Top Tech Stocks to ConsiderThese 3 Stocks Have Huge Last 12 Months Shareholder YieldsHow to Most Effectively Use the MarketBeat Earnings ScreenerProminent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in uniQure Right Now?Before you consider uniQure, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here